9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma

ConditionAdvanced Malignant Pleural MesotheliomaEstimated Enrollment: 26Age Group: 18 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: INCANOGAR2012-JA3Study First Received: April 18, 2012Last Updated: March 1, 2017Estimated Primary Completion Date: December 2017Primary Outcome Measures:Evaluate adverse effects to 250 mg/m2 infusion gemcitabine|Progression Free Survival|overall survivalSponsors and Collaborators:Instituto Nacional de Cancerologia de Mexico|National Council of Science and Technology, MexicoResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01869023...

Continue reading

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

ConditionMalignant MesotheliomaEstimated Enrollment: 47Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: ProspectiveStudy ID Numbers: CALGB-150509|U10CA031946|CDR0000491313Study First Received: May 9, 2009Last Updated: July 1, 2016Estimated Primary Completion Date: March 2006Primary Outcome Measures:Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)|Effect of biomarker expression level on overall survivalSponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00898547...

Continue reading

Malignant Mesothelioma – Can we Improve Quality of Life

ConditionMesothelioma, MalignantEstimated Enrollment: 319Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive CareStudy ID Numbers: PHT/2013/46Study First Received: January 4, 2017Last Updated: March 1, 2017Estimated Primary Completion Date: March 2017Primary Outcome Measures:EORTC C-30 Quality of Life|Health Related Quality of Life (HRQoL) in Patients|Patient Mood|Primary Caregiver Health Related Quality of Life (HRQoL)|Primary Caregiver Mood|Overall Survival between the two study groups|Healthcare Utilisation between the two study groups|Primary caregiver satisfaction with end of life careSponsors and Collaborators:Portsmouth Hospitals NHS Trust|British Lung Foundation|University of OxfordResult Received: No Study Results PostedWebsite...

Continue reading

Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients

ConditionMalignant MesotheliomaEstimated Enrollment: 100Age Group: Child, Adult, SeniorGender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: ProspectiveStudy ID Numbers: ONC/OSS-02/2011Study First Received: May 27, 2013Last Updated: July 20, 2016Estimated Primary Completion Date: December 2017Primary Outcome Measures:dissect the molecular mechanisms underlying the development of malignant mesothelioma|study of the effect of TAMs|investigation of molecular mechanisms linking macrophages|molecular characterization (proteome) of TAMs and tumor cells|compare in specimens from mesothelioma patients and the candidate molecular markers|Investigate the association of selected markers with Overall SurvivalSponsors and Collaborators:Armando Santoro, MD|Istituto Clinico HumanitasResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02300883...

Continue reading

Response Evaluation in Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 150Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: RetrospectiveStudy ID Numbers: ONC/OSS-02/2009Study First Received: August 6, 2009Last Updated: August 5, 2015Estimated Primary Completion Date: August 2015Primary Outcome Measures:To validate a semi-automated iterative threshold-based region growing algorithm in a previously published series of patients.|To extend the analysis to another series of consecutive patients with MALIGNANT PLEURAL MESOTHELIOMA treated with first-line pemetrexed-based chemotherapy, and to perform a combined analysis of the two groups.|To validate the new liver-based threshold semi-automated algorithm on the GE ADW4.6 workstation with the algorithm...

Continue reading

Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 107Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive CareStudy ID Numbers: 11-066Study First Received: May 17, 2011Last Updated: April 17, 2017Estimated Primary Completion Date: November 2018Primary Outcome Measures:To describe the psychological needs of patients with mesothelioma.|the aim is to explore the acceptability and promise of an Internet-based discussion group for patients with mesothelioma.Sponsors and Collaborators:Memorial Sloan Kettering Cancer CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01356251...

Continue reading

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 12Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 1716-12Study First Received: October 22, 2012Last Updated: September 8, 2016Estimated Primary Completion Date: March 2017Primary Outcome Measures:Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.|Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.Sponsors and Collaborators:Virttu Biologics LimitedResult...

Continue reading

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

ConditionPleural Mesothelioma|Peritoneal MesotheliomaEstimated Enrollment: 20Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 100146|10-C-0146Study First Received: July 9, 2010Last Updated: August 31, 2016Estimated Primary Completion Date: April 2012Primary Outcome Measures:Clinical Response Rate (PR+CR)|Safety of IMC-A12 in Patients With MesotheliomaSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: March 20, 2013Website Link: https://ClinicalTrials.gov/show/NCT01160458...

Continue reading